Starpharma Holdings Ltd and Makhteshim Agan Group today announced a collaboration program. This will see Starpharma’s Priostar® dendrimer technology applied to novel crop protection formulations across Makhteshim Agan’s extensive product portfolio.

Herald Sun reporters Brigid O’Connell, Lucie van den Berg and Grant McArthur featured Starpharma in a special report in The Herald Sun and The Australian online, examining cutting edge medical research being done in Melbourne.

"The home of corporate giants CSL, Mesoblast, Acrux, Biota and Starpharma, Melbourne also dominates in taking the laboratory to the marketplace: more than 85 products were on the market last year and dozens more were in trials in hopes of delivering the next generation of medical advances."

Starpharma today announced the results of an animal study which shows that a dendrimer-based formulation of doxorubicin was substantially more efficacious in treating secondary tumours of breast cancer (metastases) in lungs than the drug alone.

Starpharma today released its interim report and financial results for the half-year ended 31 December 2012.

Financial Highlights

• Reported loss $1.8M (Dec 2011: $4.7 million)
• R&D tax incentives of $6.8M reported in the half-year
• Cash position at 31 December 2012 $33.2M
• R&D tax incentive receivables at 31 December 2012 $8.1M

Starpharma today released its Appendix 4C - Quarterly Cashflow Report for the period ended 31 December 2012.

The Herald Sun’s Chief Business Writer John Beveridge investigates some of the best strategies to make money on the stock market and profiles Starpharma as having potential, following the results of its Phase III trial for VivaGel as a treatment for BV:

All is not lost, though, because VivaGel still has potential to become the most effective treatment for the complaint and the company's dendrimer technology has numerous other lucrative applications.

In this issue:

›  Phase 3 clinical trial results for treatment of bacterial vaginosis

› Rapid resolution of symptoms; strong patient acceptability for VivaGel^®

› Taxotere’s anti-cancer effect boosted with Starpharma’s dendrimer technology

› Turning over a new leaf in the world of agrochemicals

› Starpharma wins Janssen Company of the Year Award

Download: Shareholder Update: December 2012 ( pdf file, 1MB)

Starpharma today announced the appointment of an additional Vice President of Business Development with extensive pharmaceutical licensing experience.  Ms Eve Williamson, who will commence in the role with Starpharma in the New Year, has worked in the pharmaceutical industry for more than 20 years including senior roles in business development, marketing and sales, pricing and reimbursement, and clinical research.

Starpharma today announced the results of animal trials which show its dendrimer-enhanced version of docetaxel had significantly superior anti-cancer effects across a range of important cancer types when compared to Taxotere (docetaxel).

Starpharma released its AGM Chairman's address and CEO presentation for the meeting held 30th November 2012. Results of voting were released following the meeting.